INVENT Pharmaceuticals is focused on advancing its first line of innovative drug candidates into human clinical trials within 9-12 months. The development timeline for INVENT's pipeline of drug candidates and their potential share of the world market is estimated at up to $10 Billion.

INVENT's management team is experienced with a proven track record in drug discovery and development, and in the management and success of several publicly listed pharmaceutical and biotech companies.  Dr. Dale  Dhanoa, PhD, President and CEO of INVENT has over 20 years experience with major pharmaceutical and biotech companies including Merck where he designed and developed cardiovascular and pulmonary hypertension drugs. He has also been associated with Predix Pharma, 3-Dimensional Pharmaceuticals, Alanex and Synaptic Pharmaceutical, all of which either went public or were acquired by large pharmaceutical companies.

Recent transactions in INVENT"S drug development space include GlaxoSmithKline's $1.2 Billion alliance with Epix Pharmaceuticals for their Alzheimer's drug discovered by Dr. Dhanoa, Syryxx $300 million acquisition by Takeda, Novartis $880 million acquisition of Speedel Pharma and Gilead's acquisition for $2.2 billion of Mycogen.

SOURCE American Diversified Holdings Corporation